NextCure’s Q2 GAAP loss per share deepened to $2.80, missing estimates by $0.88 amid declining cash reserves.
NextCure reported a Q2 GAAP loss of $2.80 per share, missing expectations by $0.88. The wider-than-anticipated loss reflects ongoing operational challenges for the biotech firm.
Cash and equivalents fell to $20.1 million as of June 30, 2026, down from $41.8 million at the end of 2025. The $21.7 million decline was driven by cash used for operations and investments.
No immediate market reaction was disclosed in the release.